Utidelone Treated for the Recurrent or Metastatic Urothelial Carcinoma
Status:
Recruiting
Trial end date:
2025-12-13
Target enrollment:
Participant gender:
Summary
This study is a open-label, multicenter, phase II study to evaluate the efficacy and safety
of utidelone in the recurrent or metastatic urothelial carcinoma after prior chemotherapy.
Phase:
Phase 2
Details
Lead Sponsor:
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University